At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
AUPH Aurinia Pharmaceuticals
Market Closed 12-05 16:00:00 EST
15.62
+0.31
+2.02%
盘后15.77
+0.15+0.96%
19:20 EST
High15.65Low14.98Vol1.50M
Open15.36D1 Closing15.31Amplitude4.34%
Mkt Cap2.06BTradable Cap2.00BTotal Shares131.84M
T/O22.97MT/O Rate1.17%Tradable Shares128.06M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Aurinia Pharmaceuticals Shares Fall After Leerink Partners Downgrade
MT Newswires Live  ·  12-04
Aurinia Pharmaceuticals Shares Fall After Leerink Partners Downgrade
Aurinia Pharmaceuticals Cut to Market Perform From Outperform by Leerink Partners
Dow Jones  ·  12-03
Aurinia Pharmaceuticals Cut to Market Perform From Outperform by Leerink Partners
Leerink Partners Downgrades Aurinia Pharmaceuticals to Market Perform From Outperform, Adjusts PT to $16 From $15
MT Newswires Live  ·  12-03
Leerink Partners Downgrades Aurinia Pharmaceuticals to Market Perform From Outperform, Adjusts PT to $16 From $15
Aurinia Pharmaceuticals Inc : Leerink Partners Cuts to Market Perform From Outperform; Raises Target Price to $16 From $15
THOMSON REUTERS  ·  12-03
Aurinia Pharmaceuticals Inc : Leerink Partners Cuts to Market Perform From Outperform; Raises Target Price to $16 From $15
A Look at Aurinia Pharmaceuticals (NasdaqGM:AUPH) Valuation Following Recent Share Price Gains
Simply Wall St.  ·  11-28
A Look at Aurinia Pharmaceuticals (NasdaqGM:AUPH) Valuation Following Recent Share Price Gains
Aurinia Pharmaceuticals Q3 Operating Income USD 29.745 Million
Reuters  ·  11-20
Aurinia Pharmaceuticals Q3 Operating Income USD 29.745 Million
Stock Track | Aurinia Pharmaceuticals Soars 5.04% Following Strong Q3 Results and Raised 2025 Guidance
Stock Track  ·  11-12
Stock Track | Aurinia Pharmaceuticals Soars 5.04% Following Strong Q3 Results and Raised 2025 Guidance
Aurinia Pharmaceuticals (NasdaqGM:AUPH): Valuation Insights Following Strong Q3 Results and Raised 2025 Guidance
Simply Wall St.  ·  11-11
Aurinia Pharmaceuticals (NasdaqGM:AUPH): Valuation Insights Following Strong Q3 Results and Raised 2025 Guidance
Aurinia Pharmaceuticals Shares Rise After Jefferies Upgrade
MT Newswires Live  ·  11-08
Aurinia Pharmaceuticals Shares Rise After Jefferies Upgrade
Stock Track | Aurinia Pharmaceuticals Soars 9.23% Pre-Market on Jefferies Upgrade and Doubled Price Target
Stock Track  ·  11-07
Stock Track | Aurinia Pharmaceuticals Soars 9.23% Pre-Market on Jefferies Upgrade and Doubled Price Target
Aurinia Pharmaceuticals Raised to Buy From Hold by Jefferies
Dow Jones  ·  11-07
Aurinia Pharmaceuticals Raised to Buy From Hold by Jefferies
Aurinia Pharmaceuticals upgraded to Buy from Hold at Jefferies
TIPRANKS  ·  11-07
Aurinia Pharmaceuticals upgraded to Buy from Hold at Jefferies
Bloom Burton downgrades Aurinia Pharmaceuticals (AUPH) to a Hold
TIPRANKS  ·  11-06
Bloom Burton downgrades Aurinia Pharmaceuticals (AUPH) to a Hold
Stock Track | Aurinia Pharmaceuticals Plummets 5.05% Following RBC Downgrade to Sector Perform
Stock Track  ·  11-05
Stock Track | Aurinia Pharmaceuticals Plummets 5.05% Following RBC Downgrade to Sector Perform
Aurinia Pharmaceuticals Cut to Sector Perform From Outperform by RBC Capital
Dow Jones  ·  11-05
Aurinia Pharmaceuticals Cut to Sector Perform From Outperform by RBC Capital
RBC Downgrades Aurinia Pharmaceuticals to Sector Perform From Outperform, Raises Price Target to $15 From $9, Keeps Speculative Risk
MT Newswires Live  ·  11-05
RBC Downgrades Aurinia Pharmaceuticals to Sector Perform From Outperform, Raises Price Target to $15 From $9, Keeps Speculative Risk
H.C. Wainwright Keeps Their Buy Rating on Aurinia Pharmaceuticals (AUPH)
TIPRANKS  ·  11-05
H.C. Wainwright Keeps Their Buy Rating on Aurinia Pharmaceuticals (AUPH)
Aurinia Pharmaceuticals (AUPH) was downgraded to a Hold Rating at RBC Capital
TIPRANKS  ·  11-05
Aurinia Pharmaceuticals (AUPH) was downgraded to a Hold Rating at RBC Capital
Promising Sales and Market Potential of Lupkynis Drive Buy Rating for Aurinia Pharmaceuticals
TIPRANKS  ·  11-05
Promising Sales and Market Potential of Lupkynis Drive Buy Rating for Aurinia Pharmaceuticals
Aurinia Pharmaceuticals Inc : Leerink Partners Raises Target Price to $15 From $12
THOMSON REUTERS  ·  11-04
Aurinia Pharmaceuticals Inc : Leerink Partners Raises Target Price to $15 From $12

Introduction

Company Name.
Aurinia Pharmaceuticals
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. The company also offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. Aurinia Pharmaceuticals Inc. is headquartered in Victoria, Canada.
Issue price:
--